Complete proposals to the Extraordinary General Meeting of Alzinova later today, 27 February 2020

On 13 February 2020, Alzinova AB (“Alzinova”) convened an Extraordinary General Meeting for later today, 27 February 2020. The Company can now present the finalized proposals regarding the number of board members of the Company and the appointment of a new board member.

The proposals suggest that the Board of Directors shall comprise five members up until the end of the next Annual General Meeting. It is further proposed that Pernilla Sandwall is elected as new member of the board for the period up until the end of the next Annual General Meeting.

Pernilla has 30 years of experience from the pharmaceutical and biotech industries. She has worked in clinical research, for example as project manager and manager as well as in strategic work in clinical research at Merck & Co. Inc. (MSD). Since 2012, Pernilla has served as Chief Operating Officer for InDex Pharmaceuticals Holding AB (publ). She is currently a member of the board of the industry organization IML (Innovativa Mindre Life Science Bolag). Pernilla is independent in relation to the Company, its senior management and its major shareholders.

The existing board members Björn Larsson, Clas Malmeström, Carol Routledge and Anders Waas will remain on the board with Björn Larsson as Chairman for the period up until the end of the next Annual General Meeting.

For more information, please contact:

Kristina Torfgård, CEO

Telephone: +46 70 846 79 75


Certified Adviser:

Corpura Fondkommission AB


Telephone: 0768-532822

Home page:

About Alzinova AB  

Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer’s disease – one of our major health scourges, without efficient treatment options. The Company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is under preclinical development, in preparation for human clinical trials. Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Om oss

Alzinova AB bedriver forskning och utveckling av läkemedel för behandling av Alzheimers sjukdom. Bolagets patenterade teknologi möjliggör utveckling av nya terapier med potential att med stor träffsäkerhet angripa de skadliga ämnen som är centrala för sjukdomens uppkomst. Alzinovas fokus är utveckling av ett vaccin som ett långverkande och kostnadseffektivt läkemedel för behandling och förebyggande av Alzheimers sjukdom.


Dokument & länkar